RxDoctor Payments Data

Felix Sosa, MD

Internal Medicine · Merritt Island, FLNPI 1881799880

Payments from drug & device makers

$1,003in general payments, 2019–2025

Across 58 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$252
  • Amgen$246
  • Abbott$84
  • Pfizer$67
  • Lilly USA, LLC$53
  • AstraZeneca$46
  • plus $255 from 11 others

What the payments were for

  • Consulting fees$51%
  • Food & beverage$99899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,003 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$267,371
Medicare patients
491
Services billed
4,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide229$273,421
EliquisApixaban138$139,266
MounjaroTirzepatide74$87,815
Repatha SureclickEvolocumab52$56,022
OxycontinOxycodone Hcl28$51,923
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$46,887
XareltoRivaroxaban41$40,603
Tresiba Flextouch U-200Insulin Degludec31$39,531
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$38,295
LinzessLinaclotide43$34,839
TymlosAbaloparatide12$31,367
EntrestoSacubitril/Valsartan37$30,452
JanuviaSitagliptin Phosphate33$29,381
Repatha SyringeEvolocumab23$26,483
TrulicityDulaglutide21$25,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$252$273,421229 claims
PfizerEliquis$67$139,266138 claims
Lilly USA, LLCMounjaro, Trulicity$53$113,47995 claims
AbbVieLinzess, Creon$15$52,75359 claims
GSKTrelegy Ellipta$18$46,88746 claims
AstraZenecaFarxiga, Symbicort$46$38,66658 claims
NovartisEntresto$20$30,45237 claims
MerckJanuvia$13$29,38133 claims
Boehringer IngelheimJardiance$34$20,17816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Merritt Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →